MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Bonomarlot Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Bonomarlot (Bone-marrow Cytomax A-20) is an oral Khavinson peptide bioregulator: a complex of short bone-marrow-derived peptides marketed to support the hematopoietic and immune systems. Rather than hitting a receptor, this peptide class is proposed to enter cell nuclei and bind tissue-specific gene promoters, nudging the expression of genes that govern blood-cell proliferation and differentiation (PMC8619776). It is sold as 0.2 g capsules, and the usual Bonomarlot dosage is about 10-20 mg/day (1-2 caps) with food, run as a 20-30 day intensive course then short 10-day pulses every 2-3 months. Free-peptide half-life is very short (minutes), but the gene-regulatory effect is thought to outlast plasma levels, hence pulsed courses. Evidence is largely Russian animal and review data; independently replicated human trials specific to Bonomarlot are lacking. It is not FDA- or EMA-approved and is offered for research and educational use only.
Reconstitute: Add 1 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 10-20 mg/day orally (1-2 caps)
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Capsules: store below 25 °C, protected from light and moisture; do not freeze the finished capsules. For the educational lyophilized-vial model on this page: keep powder frozen at −20 °C; after reconstitution, refrigerate the solution at 2-8 °C and use within roughly 2-4 weeks.
Half-life: Not formally published; free ultrashort-peptide plasma half-life is estimated in minutes, while the proposed gene-regulatory effect outlasts plasma levels, supporting pulsed multi-week courses.
Route: Oral 0.2 g capsules (~10-20 mg/day with food); modeled here as a subcutaneous reconstitution reference for measurement only, not the real route.
Status: Not FDA- or EMA-approved; sold as a dietary supplement / research item with no recognized clinical indication. Educational content, not medical advice.
About Bonomarlot
Bonomarlot (Bone-marrow Cytomax A-20) is an oral Khavinson peptide bioregulator: a complex of short bone-marrow-derived peptides positioned as a tissue-specific regulator of the hematopoietic and immune systems [1][2]. In real-world use it is swallowed as 0.2 g capsules, not injected; the subcutaneous reconstitution scheme shown here is an educational measurement reference used across this site so the figures map onto a familiar syringe, not a clinically validated delivery route.\n\nThe most widely cited Bonomarlot dosage is 1-2 capsules (roughly 10-20 mg of peptide complex) per day with meals. A typical protocol begins with an intensive 20-30 day course at 2 capsules daily, then steps down to short 10-day maintenance pulses every two to three months [8]. Lower-intensity or older users often start at a single capsule per day to assess tolerance before titrating up.\n\nFor the educational subcutaneous model, a 20 mg vial reconstituted with 1.0 mL of bacteriostatic water gives 20 mg/mL, so 10 mg measures 50 units and 20 mg measures 100 units (one full U-100 insulin syringe). These are large unit volumes for a peptide, which is itself a reminder that Bonomarlot is dosed orally in milligram capsules rather than injected.\n\nFrequency: Once daily by mouth with food during each course; courses are pulsed (e.g., 20-30 days on, then 10-day refreshers every 2-3 months) rather than taken continuously year-round. Bonomarlot is not FDA- or EMA-approved and is presented here for educational purposes only, not as medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe (this yields 20 mg/mL from a 20 mg vial, i.e. 200 mcg per insulin-syringe unit).
Inject the water slowly down the inner wall of the vial; do not aim the stream directly at the peptide and avoid vigorous shaking or foaming.
Gently swirl or roll the vial until the solution is completely clear; do not shake, as agitation can degrade the peptide.
Store the reconstituted solution refrigerated at 2-8 °C; draw the prescribed units per dose (10 mg ≈ 50 units, 20 mg ≈ 100 units = one full U-100 syringe).
Educational note: Bonomarlot is clinically taken ORALLY as capsules — these subcutaneous reconstitution figures are a measurement reference only; for any subcutaneous educational modeling, inject slowly, do not aspirate, and wait a few seconds before withdrawing the needle.
Interactive Bonomarlot Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 1mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Days 1-5 — introductory / lower-intensity (≈1 capsule) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Standard intensive course, Day 6-30 (≈2 capsules/day) | 20000 mcg (20 mg) | 100 units (1.00 mL) |
| Maintenance pulse — 10 days every 2-3 months | 20000 mcg (20 mg) | 100 units (1.00 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Bonomarlot, 20 mg each):
- check8-week continuous model at 20 mg/day ≈ 56 vials (1,120 mg total)
- check12 weeks at 20 mg/day ≈ 84 vials (1,680 mg total)
- check16 weeks at 20 mg/day ≈ 112 vials (2,240 mg total) — the high count illustrates why Bonomarlot is taken as oral capsules, and why real protocols pulse courses rather than dose continuously
Insulin Syringes (U-100):
- checkOnce-daily dosing: 7 syringes per week
- check8 weeks ≈ 56 syringes; 12 weeks ≈ 84 syringes; 16 weeks ≈ 112 syringes
- checkA 20 mg dose fills one full 1 mL syringe (≈100 units); a 10 mg intro dose ≈ 50 units
Bacteriostatic Water (30 mL bottles): Use 1 mL per 20 mg vial for reconstitution.
- check8 weeks (20 mg/day) ≈ 56 mL ≈ 2 bottles
- check12 weeks ≈ 84 mL ≈ 3 bottles
- check16 weeks ≈ 112 mL ≈ 4 bottles
Alcohol Swabs:
- check1-2 swabs per dose (vial top + injection site)
- check8 weeks ≈ 60-120 swabs; 12 weeks ≈ 90-170 swabs
- check16 weeks ≈ 120-230 swabs; keep extras for re-swabbing multi-use vials
Mechanism of Action (MOA)
Bonomarlot belongs to the family of peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson [2][7]. It is not a single defined molecule but a low-molecular-weight complex of peptide fractions (predominantly di-, tri-, and tetrapeptides) extracted and purified from the bone marrow of young animals. In Khavinson nomenclature, naturally extracted complexes like this are termed \"cytomaxes\" (or cytamins), distinct from the fully synthetic single-sequence \"cytogens\" [4][7].\n\nThe proposed mechanism is genetic rather than receptor-mediated. The systematic review literature describes short peptides penetrating the cell membrane and entering the nucleus and nucleolus, where they bind complementary nucleotide sequences in gene promoter regions, locally weaken the DNA double helix, and facilitate strand separation needed for transcription [1][5]. In this model, tissue-specific peptide complexes preferentially up- or down-regulate the genes of the tissue they were derived from, so a bone-marrow complex is hypothesized to influence transcription programs governing proliferation and differentiation of hematopoietic and immune cell lines [1][2]. Peptides in this class have also been characterized as epigenetic modulators, affecting DNA methylation status and histone interactions, which is offered as the basis for durable, tissue-targeted effects [6]. The intended downstream result is normalization of bone-marrow metabolic activity and support of red cell, white cell, and platelet production, particularly where hematopoiesis has been impaired by aging, illness, malnutrition, or environmental stress.\n\nPharmacokinetics for Bonomarlot specifically have not been formally published. Based on the chemistry of ultrashort peptides, the free-peptide plasma half-life is expected to be very short, on the order of minutes, as small peptides are rapidly hydrolyzed by serum and tissue peptidases. Oral bioavailability of intact peptides is correspondingly low; the working assumption in this literature is that fragments and signaling activity reach target tissues and that the biological (gene-regulatory) effect outlasts measurable plasma peptide, which is the stated rationale for pulsed courses (e.g., a 20-30 day loading course followed by brief 10-day refreshers every 2-3 months) rather than indefinite daily dosing [4][8]. There is no established receptor occupancy, no dose-response curve from controlled human pharmacology, and no validated biomarker of target engagement in indexed Western trials.\n\nIt is important to be clear about the evidence ceiling. Most supporting data for the bioregulator class come from experimental animal work and Russian-language reviews reporting lifespan extension and shifts in gene expression and immune markers [3][4]. Direct, independently replicated, peer-reviewed human randomized trials of Bonomarlot for anemia or hematopoietic restoration are not available in PubMed; manufacturer materials reference clinical use but do not point to indexed controlled trials [8]. The compound is therefore best understood as an investigational/educational nutraceutical, not a proven hematologic therapy. The real route is oral; the subcutaneous reconstitution scheme on this page is a site-wide measurement convention, not a clinical delivery method.
Clinical Trial Efficacy Highlights
- starKhavinson's foundational review (Peptides and Ageing, Neuroendocrinology Letters, 2002) established the tissue-specificity principle behind cytomax complexes like Bonomarlot, showing that organ-derived peptide preparations stimulated outgrowth of explants from their own tissue of origin but not from unrelated tissues, the conceptual basis for a bone-marrow complex acting selectively on hematopoietic tissue [2].
- starAnisimov and Khavinson (Biogerontology, 2010) summarized long-term rodent studies in which peptide bioregulator preparations increased mean lifespan by roughly 20-40% and suppressed spontaneous and induced tumorigenesis, evidence that supports the class but was generated with related preparations rather than Bonomarlot specifically [3].
- starKhavinson, Kuznik and Ryzhak (Advances in Gerontology, 2012) reviewed the experimental basis for peptide bioregulators as a class of geroprotectors, concluding that these short-peptide complexes can extend lifespan and inhibit carcinogenesis in laboratory animals, while emphasizing that the data derive largely from Russian experimental programs [4].
- starThe systematic review by Khavinson and colleagues (Molecules, 2021) catalogued how short peptides regulate gene expression, reporting that defined sequences such as AEDG and KE modulate dozens of genes (98 and 36 genes, respectively) through sequence-specific promoter binding, providing the mechanistic plausibility invoked for tissue-targeted complexes like Bonomarlot [1].
- starJanssens and colleagues (Clinical Epigenetics, 2019) independently reviewed peptides as epigenetic modulators, describing short peptides that interact with DNA in promoter regions to influence transcription and DNA methylation, offering a non-Khavinson source consistent with the proposed gene-regulatory mode of action [6].
- starIlina, Khavinson and colleagues (International Journal of Molecular Sciences, 2022) detailed neuroepigenetic mechanisms of ultrashort peptides, including nuclear penetration and direct DNA binding, reinforcing the model that this peptide class acts at the level of gene regulation rather than classical receptor signaling [5].
- starCritically, no independently replicated, peer-reviewed randomized controlled trial of Bonomarlot for anemia or hematopoietic recovery is indexed in PubMed; manufacturer literature cites clinical use and a hematopoietic indication but does not reference controlled trial data, so efficacy claims should be treated as preliminary and unproven [8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningBonomarlot is generally marketed as well tolerated with the manufacturer claiming "no side effects," but this reflects an absence of formal safety trials rather than demonstrated safety; the lack of indexed adverse-event data is itself a limitation [8].
- warningHypersensitivity or allergic reactions to the peptide complex or capsule excipients are possible; the only listed contraindication is intolerance to the components, plus pregnancy and breastfeeding without physician supervision [8].
- warningBecause the active material is an animal-tissue (bone-marrow) extract, there is a theoretical risk of biological contaminants; product purity, peptide content, and freedom from pathogens depend entirely on the manufacturer, and these are not FDA-regulated drug products [7].
- warningNo human pharmacokinetic, drug-interaction, or organ-toxicity studies are published, so interactions with prescription medications (including immunosuppressants, anticoagulants, or chemotherapy) are unknown and unpredictable.
- warningBonomarlot should not be used as a substitute for medical evaluation and treatment of anemia, cytopenias, or other blood disorders; serious hematologic conditions require diagnosis and management by a qualified clinician, not an unproven supplement.
- warningLong-term safety is not established; the geroprotective and gene-regulatory claims for the bioregulator class come largely from animal models and non-replicated reviews, and durable up-regulation of cell proliferation pathways has not been characterized for safety in humans [3][4].
- warningThe subcutaneous route modeled on this page is not how Bonomarlot is used; injecting an oral capsule product is not supported and carries infection, sterility, and unknown-impurity risks. The figures here are strictly an educational measurement reference.
- warningRegulatory/research status: Bonomarlot is not approved by the FDA or EMA as a drug, is sold as a dietary supplement or research item, and has no recognized clinical indication in the United States or European Union [7].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Bonomarlot dosage?expand_more
The most commonly cited Bonomarlot dosage is 1-2 capsules per day (roughly 10-20 mg of bone-marrow peptide complex) taken with meals. A standard protocol uses an intensive 20-30 day course at 2 capsules daily, then short 10-day maintenance pulses every two to three months; lower-intensity or older users often start at 1 capsule per day. Bonomarlot is taken orally as 0.2 g capsules, not injected; the subcutaneous units shown on this page are an educational measurement reference only. There is no controlled-trial dose-response data, so these figures reflect manufacturer guidance rather than validated clinical dosing.
Is Bonomarlot FDA approved?expand_more
No. Bonomarlot is not approved by the FDA or the EMA as a drug for any indication. It is a Russian-origin peptide bioregulator sold as a dietary supplement or research-use product, with no recognized clinical indication in the United States or European Union. Manufacturer claims of hematopoietic benefit are not backed by independently replicated, peer-reviewed randomized trials indexed in PubMed. Treat any use as educational and experimental, and consult a qualified clinician for anemia or any blood disorder rather than self-treating.
What is the half-life of Bonomarlot?expand_more
There is no published pharmacokinetic study for Bonomarlot. Because it consists of ultrashort peptides (di-, tri-, and tetrapeptides), the free-peptide plasma half-life is expected to be very short, on the order of minutes, as small peptides are rapidly broken down by serum and tissue peptidases. The proposed gene-regulatory effect is thought to outlast measurable plasma peptide, which is the stated rationale for pulsed multi-week courses (loading course plus periodic 10-day refreshers) instead of continuous year-round dosing.
How is Bonomarlot reconstituted and administered?expand_more
In real-world use Bonomarlot is swallowed as a capsule, so no reconstitution is needed. For the educational subcutaneous model on this site, a 20 mg vial is mixed with 1.0 mL of bacteriostatic water to give 20 mg/mL: draw the water slowly down the vial wall, swirl gently until clear, and refrigerate. At that concentration 10 mg measures about 50 units and 20 mg about 100 units (one full U-100 insulin syringe). These are unusually large injection volumes for a peptide, which underlines that Bonomarlot is intended to be taken orally, not injected.
Can Bonomarlot be stacked with other Khavinson peptide bioregulators?expand_more
Within the Khavinson framework, tissue-specific bioregulators are often combined (for example a bone-marrow complex alongside thymus- or immune-targeted peptides) on the theory that each acts on its own tissue's genes. However, there are no controlled studies validating any specific Bonomarlot stack, and no human drug-interaction data exist. Combining unregulated animal-extract supplements compounds the uncertainty about purity, dose, and interactions. Any stacking should be considered experimental and discussed with a clinician, especially for anyone with a blood, immune, or oncologic condition.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Bonomarlot, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies. Adv Gerontol. 2012;25(4):696-708. View Scientific Paper →
Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease. Int J Mol Sci. 2022;23(8):4259. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. View Scientific Paper →
Vladimir Khavinson — biography and peptide bioregulator research program, St. Petersburg Institute of Bioregulation and Gerontology (Wikipedia overview). View Scientific Paper →
Bonomarlot (A-20 bone marrow peptide bioregulator) — product composition, capsule size and recommended dosing course. CosmicNootropic product listing. View Scientific Paper →